Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry
Objectives: The management of patients with multifocal motor neuropathy (MMN) under everyday clinical conditions has been insufficiently studied. We therefore collected comprehensive observational data on patients with MMN who received intravenous (IV) or subcutaneous (SC) immunoglobulins (IGs) as m...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-05-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/1756285616629869 |
| _version_ | 1818517929152479232 |
|---|---|
| author | Martin Stangel Ralf Gold David Pittrow Ulrich Baumann Michael Borte Maria Fasshauer Manfred Hensel Dörte Huscher Marcel Reiser Claudia Sommer |
| author_facet | Martin Stangel Ralf Gold David Pittrow Ulrich Baumann Michael Borte Maria Fasshauer Manfred Hensel Dörte Huscher Marcel Reiser Claudia Sommer |
| author_sort | Martin Stangel |
| collection | DOAJ |
| description | Objectives: The management of patients with multifocal motor neuropathy (MMN) under everyday clinical conditions has been insufficiently studied. We therefore collected comprehensive observational data on patients with MMN who received intravenous (IV) or subcutaneous (SC) immunoglobulins (IGs) as maintenance therapy. Methods: This was a prospective, noninterventional study (registry) in neurological centres (hospitals and offices) throughout Germany. Results: As of 1 December 2015, 80 patients with MMN were included (mean age 55.4 ± 9.8 years, 67% males, mean disease duration 10.7 ± 10.2 years). The affected limb regions were predominantly distal muscle groups of the upper extremities. On the inflammatory neuropathy cause and treatment (INCAT) scale, 94% of the patients had some disability in the arms and 61% in the legs. At inclusion, 98.8% received IVIG and 1.3% SCIG. Substantial variation was observed between IVIG treatment intervals (every 0.7 to 17.3 weeks) and dosage (0.2–2.1 g/kg body weight received during a single administration; mean monthly dosage, 0.9 g/kg body weight). However, the mean monthly dosage was steady over time. At 1-year follow up, improvement was seen in muscle strength, INCAT and quality of life (QoL) scores (SF-36 questionnaire). Conclusions: The management of patients with MMN in everyday clinical practice demonstrates a wide range of absolute dosages and treatment intervals of IG, supporting the recommended practice of determining treatment dose on an individual patient basis. The improvements in muscle strength and reduction in disability, accompanied by increased QoL, strengthen the case for use of IG as a maintenance treatment for MMN. |
| first_indexed | 2024-12-11T01:02:54Z |
| format | Article |
| id | doaj.art-a3e12196c6d44958a2f3319aa76d18e8 |
| institution | Directory Open Access Journal |
| issn | 1756-2856 1756-2864 |
| language | English |
| last_indexed | 2024-12-11T01:02:54Z |
| publishDate | 2016-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-a3e12196c6d44958a2f3319aa76d18e82022-12-22T01:26:16ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642016-05-01910.1177/1756285616629869Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryMartin StangelRalf GoldDavid PittrowUlrich BaumannMichael BorteMaria FasshauerManfred HenselDörte HuscherMarcel ReiserClaudia SommerObjectives: The management of patients with multifocal motor neuropathy (MMN) under everyday clinical conditions has been insufficiently studied. We therefore collected comprehensive observational data on patients with MMN who received intravenous (IV) or subcutaneous (SC) immunoglobulins (IGs) as maintenance therapy. Methods: This was a prospective, noninterventional study (registry) in neurological centres (hospitals and offices) throughout Germany. Results: As of 1 December 2015, 80 patients with MMN were included (mean age 55.4 ± 9.8 years, 67% males, mean disease duration 10.7 ± 10.2 years). The affected limb regions were predominantly distal muscle groups of the upper extremities. On the inflammatory neuropathy cause and treatment (INCAT) scale, 94% of the patients had some disability in the arms and 61% in the legs. At inclusion, 98.8% received IVIG and 1.3% SCIG. Substantial variation was observed between IVIG treatment intervals (every 0.7 to 17.3 weeks) and dosage (0.2–2.1 g/kg body weight received during a single administration; mean monthly dosage, 0.9 g/kg body weight). However, the mean monthly dosage was steady over time. At 1-year follow up, improvement was seen in muscle strength, INCAT and quality of life (QoL) scores (SF-36 questionnaire). Conclusions: The management of patients with MMN in everyday clinical practice demonstrates a wide range of absolute dosages and treatment intervals of IG, supporting the recommended practice of determining treatment dose on an individual patient basis. The improvements in muscle strength and reduction in disability, accompanied by increased QoL, strengthen the case for use of IG as a maintenance treatment for MMN.https://doi.org/10.1177/1756285616629869 |
| spellingShingle | Martin Stangel Ralf Gold David Pittrow Ulrich Baumann Michael Borte Maria Fasshauer Manfred Hensel Dörte Huscher Marcel Reiser Claudia Sommer Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry Therapeutic Advances in Neurological Disorders |
| title | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| title_full | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| title_fullStr | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| title_full_unstemmed | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| title_short | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| title_sort | treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice the signs registry |
| url | https://doi.org/10.1177/1756285616629869 |
| work_keys_str_mv | AT martinstangel treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT ralfgold treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT davidpittrow treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT ulrichbaumann treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT michaelborte treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT mariafasshauer treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT manfredhensel treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT dortehuscher treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT marcelreiser treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry AT claudiasommer treatmentofpatientswithmultifocalmotorneuropathywithimmunoglobulinsinclinicalpracticethesignsregistry |